BAGSVAERD, DENMARK--(Marketwire - February 11, 2010) -
Novo Nordisk files annual report with the SEC
Novo Nordisk A/S has filed its Annual Report 2009 on Form 20-F for the financial year 2009 with the US Securities and Exchange Commission (SEC), incorporating by reference the Novo Nordisk A/S Annual Report 2009. The reports are available at the SEC’s website, www.sec.gov as well as at novonordisk.com (http://www.novonordisk.com/) - Investors - Download centre (listed under 2009).
Shareholders and ADR holders may receive a hard copy of the annual reports free of charge upon request by filling out a request form atnovonordisk.com/investors/download-centre (http://www.novonordisk.com/investors/download-centre) or upon request to either tel no (+1) 609 919 7937 or by e-mail to hrmm@novonordisk.com . When e-mailing, please state the exact mailing address and the document(s) you wish to receive.
* Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit novonordisk.com.
Further information: Media: Elin K Hansen Tel: (+45) 4442 3450 ekh@novonordisk.com Investors: Klaus Bulow Davidsen Tel: (+45) 4442 3176 klda@novonordisk.com Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 krop@novonordisk.com In North America: Sean Clements Tel: (+1) 609 514 8316 secl@novonordisk.com In North America: Hans Rommer Tel: (+1) 609 919 7937 hrmm@novonordisk.com
[HUG#1383594]
Further information:
Media:
Elin K Hansen
Tel: (+45) 4442 3450
Email Contact
Investors:
Klaus Bulow Davidsen
Tel: (+45) 4442 3176
Email Contact
Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
Email Contact
In North America:
Sean Clements
Tel: (+1) 609 514 8316
Email Contact
In North America:
Hans Rommer
Tel: (+1) 609 919 7937
Email Contact